 |
인쇄하기
취소
|
Alliance with AstraZeneca Korea positive for Green Cross
Green Cross Corp. said Friday it has signed an agreement with AstraZeneca Korea to co-market Atacand (candesartan cilexetil), angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Analysts say the strategic alliance between Green Cross and AstraZeneca Korea is likely to help the leading Korean vaccine maker boost its circulatory market in which the company is less...
Analysts say the strategic alliance between Green Cross and AstraZeneca Korea is likely to help the leading Korean vaccine maker boost its circulatory market in which the company is less...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.